MX2018005756A - Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. - Google Patents

Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.

Info

Publication number
MX2018005756A
MX2018005756A MX2018005756A MX2018005756A MX2018005756A MX 2018005756 A MX2018005756 A MX 2018005756A MX 2018005756 A MX2018005756 A MX 2018005756A MX 2018005756 A MX2018005756 A MX 2018005756A MX 2018005756 A MX2018005756 A MX 2018005756A
Authority
MX
Mexico
Prior art keywords
receptor
fpr2
lipoxin
alx
formyl
Prior art date
Application number
MX2018005756A
Other languages
English (en)
Inventor
Ostrowski Jacek
Garcia Ricardo
R Wurtz Nicholas
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018005756A publication Critical patent/MX2018005756A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción se refiere en general a un método terapéutico basado en la estimulación de la resolución de la inflamación por el Receptor 2 de Formilo-Péptido/receptor de Lipoxina A4 (FPR2/ALX) para el tratamiento de enfermedades cardiacas.
MX2018005756A 2015-11-24 2016-11-21 Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. MX2018005756A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (1)

Publication Number Publication Date
MX2018005756A true MX2018005756A (es) 2018-08-01

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005756A MX2018005756A (es) 2015-11-24 2016-11-21 Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.

Country Status (13)

Country Link
US (1) US20180325869A1 (es)
EP (1) EP3380091A1 (es)
JP (1) JP2018538367A (es)
KR (1) KR20180081528A (es)
CN (1) CN108348479A (es)
AU (1) AU2016359463A1 (es)
BR (1) BR112018010155A8 (es)
CA (1) CA3006291A1 (es)
EA (1) EA201891007A1 (es)
IL (1) IL259468A (es)
MX (1) MX2018005756A (es)
SG (1) SG11201803816RA (es)
WO (1) WO2017091496A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018006635A (es) 2015-12-10 2018-08-01 Squibb Bristol Myers Co Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona.
JP7183193B2 (ja) * 2017-06-09 2022-12-05 ブリストル－マイヤーズ スクイブ カンパニー ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
CN110997661B (zh) * 2017-06-09 2023-03-31 百时美施贵宝公司 环丙基脲甲酰肽2受体和甲酰肽1受体激动剂
US11124494B2 (en) 2017-06-09 2021-09-21 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
PE20210046A1 (es) 2018-03-05 2021-01-08 Bristol Myers Squibb Co Agonistas de fenilpirrolidinona del receptor 2 de formil peptido

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2492167C2 (ru) * 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные аминотриазола в качестве агонистов alх
EP2640699B1 (en) * 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Bridged spiro[2,4]heptane ester derivatives
US9284288B2 (en) * 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
MX2018006635A (es) * 2015-12-10 2018-08-01 Squibb Bristol Myers Co Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona.
PE20210046A1 (es) * 2018-03-05 2021-01-08 Bristol Myers Squibb Co Agonistas de fenilpirrolidinona del receptor 2 de formil peptido

Also Published As

Publication number Publication date
IL259468A (en) 2018-07-31
WO2017091496A1 (en) 2017-06-01
EA201891007A1 (ru) 2018-11-30
AU2016359463A1 (en) 2018-07-12
KR20180081528A (ko) 2018-07-16
US20180325869A1 (en) 2018-11-15
JP2018538367A (ja) 2018-12-27
EP3380091A1 (en) 2018-10-03
BR112018010155A2 (pt) 2018-11-21
BR112018010155A8 (pt) 2019-02-26
SG11201803816RA (en) 2018-06-28
CA3006291A1 (en) 2017-06-01
CN108348479A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
MX2018005756A (es) Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
WO2016037144A3 (en) Cardiac pacing lead delivery system
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
MX2016013049A (es) Inhibidores de autotaxina espirociclicos sustituidos.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
EP3180009A4 (en) Zoledronic acid dosage forms for the treatment of pain
MX2017013383A (es) Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
EP3429605A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
EA201790693A1 (ru) Коррекция фигуры
PH12017500493A1 (en) Combination therapy
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
EP3607963A4 (en) THERAPEUTIC DRUG FOR FIBROUS DISEASES
HK1246771A1 (zh) 用於治療心臟疾病的代謝穩健的類二十烷酸類似物
EP3285771A4 (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
EP3648769A4 (en) N-ACYL AMIDES DERIVED FROM THE HUMAN MICROBIOTE FOR THE TREATMENT OF HUMAN DISEASE
EP3902539A4 (en) METHOD OF TREATMENT OF PARKINSON'S DISEASE BY ADMINISTRATION OF RESINIFERATOXIN
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
PL3236947T3 (pl) Produkty do dostarczania związków terapeutycznych/diagnostycznych do serca
IL274744B (en) Phenoxy acids for the treatment of neuromuscular disorders
EP3658157A4 (en) TREATMENT OF HEART DISEASE BY INHIBITING THE ACTION OF KINASES A (MAKAP) ANCHORING PROTEINS IN THE MUSCLE
EP3310310A4 (en) DEVICE FOR TREATING MENIÈRE DISEASE
GB201908180D0 (en) Therapy for heart disorders
PL3710043T3 (pl) Fgf10 do leczenia chorób serca